Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (370)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (10)
Health technology evaluations (9)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (292)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 21 to 30 of 380
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable ID6218
Technology appraisal guidance
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Atogepant for preventing migraine [ID5090]
Technology appraisal guidance
15 May 2024
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
…
38
Page
3
of
38
Next page
Results per page
10
25
50
All
Back to top